Spirulina, also known as blue-green algae, is edible. It can be engineered to cost-effectively produce biologics that can be taken orally. Though people have long sought to do this, Lumen Bioscience has developed platform technology that solved the various challenges is engineering spirulina to produce medicines. We spoke to Brian Finrow, co-founder and CEO of Lumen, about the company’s platform technology, why it makes possible the pursuit of biologics for indications that were previously not practical, and the potential to make these advanced therapies affordable and accessible in parts of the world where people may not have widely enjoyed their benefits.